LSU Health Shreveport, Shreveport, LA, USA.
Kansas City University of Medicine and Biosciences, Kansas City, MO, USA.
Methods Mol Biol. 2022;2547:505-526. doi: 10.1007/978-1-0716-2573-6_18.
Pharmacogenomics can improve pain management by considering individual variations in pain perception and susceptibility and sensitivity to medicines related to genetic diversity. Due to the subjective nature of pain and the fact that people respond differently to medicines, it can be challenging to develop a consistent and successful regimen for pain disorders. Numerous factors influence the outcome of pain treatment programs, but two stand out: altered perception of pain and varying responsiveness to analgesic medicines. Numerous polymorphisms in genes such as CYP2D6, OPRM1, and ABCB1 have been identified, culminating in a heterogeneous response to pain medication in people who have these genetic polymorphisms. Improved treatment regimens that factor in pharmacogenetic differences in patients would help reduce the risk of opioid dependency and help effectively treat postoperative pain.
药物基因组学可以通过考虑与遗传多样性相关的个体对疼痛感知、药物敏感性和易感性的差异来改善疼痛管理。由于疼痛的主观性以及人们对药物反应不同，因此制定一致且成功的疼痛障碍治疗方案可能具有挑战性。许多因素会影响疼痛治疗计划的结果，但有两个因素尤为突出：疼痛感知的改变和对镇痛药的反应性不同。已经确定了 CYP2D6、OPRM1 和 ABCB1 等基因中的许多多态性，导致具有这些遗传多态性的人对疼痛药物的反应存在异质性。考虑患者药物基因组学差异的改良治疗方案将有助于降低阿片类药物依赖的风险，并有助于有效治疗术后疼痛。
